Pay in 4 interest-free payments of $6.50 Learn more
Ships within 48 hours · Estimated delivery Oct 21 - Oct 26
References Peer Reviewed Sikiric P et al
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
The primary alternatives to GHK-Cu include BPC-157, Matrixyl (Palmitoyl Pentapeptide-4)
Check the leaflet for your specific product
Small molecules can engage different administration routes than peptides typically use
